The implicated firms have strongly denied the claims, stating that their actions have been perfectly legal and that the price rises are nothing more than representative of a highly competitive market and reimbursement plans which put “an unfair burden on people with diabetes.”
Ver
No hay comentarios:
Publicar un comentario